NU 578 Unit 4 Exam | ACTUAL EXAM | Advanced Pharmacology | University of South Alabama | 75 Questions & Answers with Expert Rationales | Pass Guaranteed - A+ Graded

Pass the NU 578 Unit 4 Advanced Pharmacology Exam on your first attempt with the most current actual exam resource available. This A+ Graded comprehensive study resource contains 75 Questions with Expert Rationales fully aligned with the University of South Alabama NU 578 Advanced Pharmacology curriculum, covering Oncology, Hematology, Immunologic, and Infectious Disease pharmacology domains essential for graduate-level nursing success. Designed to mirror the official NU 578 Unit 4 Examination format, this resource provides the most thorough preparation for advanced practice nursing students seeking to demonstrate mastery of pharmacotherapeutics for complex oncologic, hematologic, immunologic, and infectious disease conditions. Comprehensive content coverage includes: ONCOLOGY PHARMACOLOGY Chemotherapeutic Agents: Alkylating agents (cyclophosphamide, cisplatin, carboplatin: mechanism, dose-limiting toxicity, hemorrhagic cystitis, nephrotoxicity), antimetabolites (methotrexate, 5-fluorouracil, gemcitabine: folate antagonism, leucovorin rescue, hand-foot syndrome), antitumor antibiotics (doxorubicin, daunorubicin: cardiotoxicity, cumulative dose limits, extravasation risk), plant alkaloids (vincristine, vinblastine: neurotoxicity, constipation, vesicant properties; paclitaxel, docetaxel: neuropathy, hypersensitivity), topoisomerase inhibitors (etoposide, irinotecan: myelosuppression, diarrhea) Targeted Therapies: Tyrosine kinase inhibitors (imatinib: CML, GIST; erlotinib, gefitinib: NSCLC; dasatinib, nilotinib; adverse effects: edema, hepatotoxicity, QT prolongation), monoclonal antibodies (trastuzumab: HER2-positive breast cancer, cardiotoxicity; rituximab: CD20-positive lymphomas, infusion reactions, hepatitis B reactivation; bevacizumab: anti-VEGF, hypertension, proteinuria, bleeding; cetuximab: infusion reactions, rash), proteasome inhibitors (bortezomib: multiple myeloma, peripheral neuropathy), mTOR inhibitors (everolimus, temsirolimus: stomatitis, hyperglycemia, pneumonitis), PARP inhibitors (olaparib, niraparib: BRCA-mutated cancers, myelosuppression) Immunotherapy: Immune checkpoint inhibitors (pembrolizumab, nivolumab: PD-1 inhibitors; ipilimumab: CTLA-4 inhibitor; immune-related adverse events: pneumonitis, colitis, hepatitis, dermatitis, endocrinopathies; irAE management with corticosteroids), CAR-T cell therapy (tisagenlecleucel, axicabtagene ciloleucel: cytokine release syndrome, neurotoxicity), cancer vaccines Hormonal Therapy: Selective estrogen receptor modulators (tamoxifen: endometrial cancer risk, thromboembolism, hot flashes; raloxifene), aromatase inhibitors (anastrozole, letrozole, exemestane: arthralgias, osteoporosis, cardiovascular risk), androgen deprivation therapy (leuprolide, goserelin: hot flashes, osteoporosis, metabolic syndrome), antiandrogens (bicalutamide, enzalutamide, apalutamide) Supportive Care in Oncology: Colony-stimulating factors (filgrastim, pegfilgrastim: neutropenia prevention, bone pain, splenic rupture), erythropoiesis-stimulating agents (epoetin alfa, darbepoetin: target hemoglobin, thrombosis risk, black box warning), antiemetics (ondansetron, арrepitant, olanzapine: chemotherapy-induced nausea and vomiting prevention), bisphosphonates (zoledronic acid, pamidronate: hypercalcemia, bone metastases, osteonecrosis of the jaw), RANKL inhibitors (denosumab: hypocalcemia, osteonecrosis of the jaw), opioid analgesics for cancer pain Chemotherapy Adverse Effects Management: Myelosuppression (neutropenia: infection risk, growth factors; thrombocytopenia: bleeding precautions; anemia: transfusion criteria), mucositis management, alopecia, hand-foot syndrome, extravasation management, tumor lysis syndrome (allopurinol, rasburicase) HEMATOLOGY PHARMACOLOGY Anticoagulants: Heparin and low-molecular-weight heparins (unfractionated heparin: aPTT monitoring, HIT; enoxaparin, dalteparin: anti-Xa monitoring, renal dosing), direct oral anticoagulants (apixaban, rivaroxaban: factor Xa inhibitors, no routine monitoring, reversal agents: andexanet alfa; dabigatran: direct thrombin inhibitor, reversal agent: idarucizumab), warfarin (vitamin K antagonist, INR monitoring, drug interactions, reversal with vitamin K, fresh frozen plasma, prothrombin complex concentrate), anticoagulant reversal strategies Antiplatelet Agents: Aspirin (irreversible COX inhibition), P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel: platelet aggregation inhibition, CYP2C19 metabolism for clopidogrel), glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban: IV antiplatelet therapy), dual antiplatelet therapy (DAPT) Thrombolytics: Alteplase (tPA), tenecteplase: indications (ischemic stroke, PE, MI), administration, contraindications, bleeding risk management Anemia Management: Iron preparations (oral ferrous sulfate, IV iron sucrose, ferric carboxymaltose: indications, adverse effects, administration), vitamin B12 (cyanocobalamin: pernicious anemia, IM or sublingual), folic acid supplementation Thrombocytopenia Management: Immune thrombocytopenia (ITP) pharmacotherapy (corticosteroids, IVIG, anti-D immunoglobulin, thrombopoietin receptor agonists: romiplostim, eltrombopag), heparin-induced thrombocytopenia (HIT) management (argatroban, bivalirudin, fondaparinux) Sickle Cell Disease: Hydroxyurea: reduces vaso-occlusive crises, fetal hemoglobin induction, monitoring; L-glutamine: reduces acute complications; crizanlizumab: P-selectin inhibitor; voxelotor: hemoglobin S polymerization inhibitor IMMUNOLOGIC PHARMACOLOGY Corticosteroids: Glucocorticoids (prednisone, methylprednisolone, hydrocortisone, dexamethasone): mechanisms, indications (autoimmune disease, inflammation, immunosuppression, allergic reactions), adverse effects (Cushing's syndrome, hyperglycemia, osteoporosis, immunosuppression, adrenal suppression), tapering protocols, stress dosing, withdrawal management, mineralocorticoid activity Immunosuppressants: Calcineurin inhibitors (tacrolimus, cyclosporine: T-cell activation inhibition, therapeutic drug monitoring, nephrotoxicity, hypertension, neurotoxicity), mTOR inhibitors (sirolimus, everolimus: T-cell proliferation inhibition, wound healing, hyperlipidemia, mouth ulcers), antimetabolites (mycophenolate mofetil, azathioprine: lymphocyte proliferation inhibition, myelosuppression, teratogenicity, GI intolerance), monoclonal antibodies for immunosuppression (basiliximab, alemtuzumab, rituximab) Biologic Response Modifiers: Tumor necrosis factor-alpha (TNF-α) inhibitors (infliximab, adalimumab, etanercept, certolizumab, golimumab): indications (RA, IBD, psoriasis), pre-treatment screening (TB, hepatitis B), adverse effects (infections, reactivation of latent infections, malignancy risk, injection/infusion reactions), JAK inhibitors (tofacitinib, baricitinib, upadacitinib: oral small molecule inhibitors, thrombosis risk, infections), interleukin inhibitors (ustekinumab: IL-12/23 inhibitor; secukinumab: IL-17 inhibitor; tocilizumab: IL-6 inhibitor) Antihistamines & Mast Cell Stabilizers: First-generation antihistamines (diphenhydramine, hydroxyzine: sedation, anticholinergic effects, cognitive impairment in elderly), second-generation antihistamines (loratadine, cetirizine, fexofenadine: less sedation, longer duration), mast cell stabilizers (cromolyn sodium, nedocromil: allergic rhinitis, asthma), leukotriene modifiers (montelukast, zafirlukast: asthma, allergic rhinitis, neuropsychiatric events black box warning) Immunizations & Vaccine Pharmacology: Vaccine types (live attenuated: MMR, varicella, nasal influenza; inactivated: polio, influenza injection; subunit: HPV, hepatitis B; toxoid: tetanus, diphtheria; conjugate: pneumococcal, meningococcal; mRNA: COVID-19), ACIP immunization schedules, immunocompromised host vaccination considerations, vaccine adverse effects, contraindications (anaphylaxis, severe allergic reaction), precautions, herd immunity, passive immunization (IVIG, specific immunoglobulins: hepatitis B, rabies, tetanus, VZV, RSV) Autoimmune Disease Pharmacotherapy: Rheumatoid arthritis (DMARDs: methotrexate, hydroxychloroquine, sulfasalazine, leflunomide; biologics: anti-TNF, anti-IL-6, anti-CD20; JAK inhibitors), systemic lupus erythematosus (hydroxychloroquine, corticosteroids, belimumab, voclosporin, immunosuppressants), psoriasis and psoriatic arthritis (topical therapies, phototherapy, methotrexate, biologics, apremilast), multiple sclerosis (disease-modifying therapies: interferons, glatiramer acetate, natalizumab, fingolimod, ocrelizumab), myasthenia gravis (pyridostigmine, corticosteroids, immunosuppressants, IVIG, plasmapheresis) INFECTIOUS DISEASE PHARMACOLOGY Antibiotic Classes: Penicillins (amoxicillin, ampicillin, piperacillin/tazobactam: beta-lactam mechanism, cross-reactivity, hypersensitivity), cephalosporins (generations 1-5: increasing gram-negative coverage, ceftriaxone, cefepime, ceftaroline), carbapenems (meropenem, ertapenem: broad spectrum, seizure risk), monobactams (aztreonam: gram-negative coverage, safe in penicillin allergy), macrolides (azithromycin, clarithromycin: atypicals, QT prolongation), tetracyclines (doxycycline, minocycline: photosensitivity, dental staining, esophagitis), aminoglycosides (gentamicin, tobramycin: gram-negative, nephrotoxicity, ototoxicity, peak/trough monitoring), fluoroquinolones (ciprofloxacin, levofloxacin: gram-negative, tendonitis, QT prolongation, neuropathy), sulfonamides (trimethoprim/sulfamethoxazole: UTI, PJP prophylaxis, Stevens-Johnson syndrome, hyperkalemia), oxazolidinones (linezolid: MRSA, VRE, serotonin syndrome, myelosuppression), lipopeptides (daptomycin: MRSA, VRE, not for pneumonia, CPK monitoring), glycylcyclines (tigecycline: broad spectrum, pancreatitis) Antimicrobial Stewardship: Principles of antimicrobial stewardship, narrow vs. broad-spectrum therapy, de-escalation, duration of therapy, culture and susceptibility testing, empiric therapy, definitive therapy, antibiotic resistance mechanisms, MDRO management (MRSA, VRE, ESBL, CRE, C. diff) Antifungal Agents: Azoles (fluconazole: Candida, cryptococcus; voriconazole: Aspergillus, therapeutic drug monitoring; itraconazole; posaconazole; isavuconazole), echinocandins (caspofungin, micafungin, anidulafungin: Candida, Aspergillus, few drug interactions), polyenes (amphotericin B: broad spectrum, nephrotoxicity, infusion reactions, electrolyte abnormalities), allylamines (terbinafine: dermatophytes), antifungal adverse effects and monitoring Antiviral Agents: Influenza antivirals (oseltamivir, zanamivir: neuraminidase inhibitors, treatment within 48 hours), herpes antivirals (acyclovir, valacyclovir, famciclovir: HSV, VZV, nephrotoxicity, CNS effects), cytomegalovirus (ganciclovir, valganciclovir, foscarnet, cidofovir: myelosuppression, nephrotoxicity), hepatitis B (entecavir, tenofovir, interferon), hepatitis C (direct-acting antivirals: sofosbuvir, ledipasvir, glecaprevir/pibrentasvir) Antiretroviral Therapy (ART): NRTIs (tenofovir, emtricitabine, abacavir: HIV backbone, renal toxicity, abacavir hypersensitivity-HLA-B*5701), NNRTIs (efavirenz, rilpivirine: CNS effects, rash), PIs (darunavir, atazanavir: GI effects, hyperlipidemia, drug interactions), integrase inhibitors (dolutegravir, bictegravir, raltegravir: high potency, well tolerated), entry inhibitors (maraviroc: CCR5 antagonist, tropism testing), fusion inhibitors (enfuvirtide: injection site reactions), PrEP (tenofovir/emtricitabine: HIV prevention), ART adverse effects, drug interactions, resistance testing Antitubercular Agents: First-line agents (isoniazid: hepatotoxicity, peripheral neuropathy, pyridoxine supplementation; rifampin: potent CYP450 inducer, orange secretions, hepatotoxicity; ethambutol: optic neuritis, red-green color discrimination; pyrazinamide: hyperuricemia, hepatotoxicity), latent TB treatment (isoniazid, rifampin, rifapentine), directly observed therapy (DOT), drug interactions, monitoring Antiparasitic Agents: Antimalarials (chloroquine, artemisinin derivatives, atovaquone/proguanil, mefloquine: neuropsychiatric effects), antiprotozoals (metronidazole: disulfiram reaction, peripheral neuropathy; tinidazole; nitazoxanide), antihelmintics (albendazole, mebendazole, ivermectin, praziquantel) Each question includes expert rationales explaining the "why" behind correct and incorrect answers, reinforcing pharmacotherapeutic principles, clinical decision-making, and evidence-based practice essential for NU 578 success. Backed by our Pass Guarantee, this comprehensive NU 578 Unit 4 Exam resource delivers the ultimate preparation for University of South Alabama advanced pharmacology students. Download now for instant access and pass with confidence.